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ABSTRACT 
 
Purpose:  The primary aim of this study was to determine the feasibility of conducting a 
randomised controlled trial (RCT) to evaluate the effectiveness of kinesiology tape (KT) and 
usual care versus usual care alone in the treatment of breast lymphoedema (BLE). 
Methods:  Fourteen participants with BLE were randomly assigned to either the KT and usual 
care group or usual care alone group.  Both groups received three sessions of manual 
lymphatic drainage (MLD) once per week for three weeks, with the KT group additionally 
wearing the KT for two seven-day periods in between MLD sessions.  Safety and acceptability 
of the KT were assessed by recording adverse events, skin changes and compliance with KT. 
Outcomes included were: ease of recruitment, attrition and acceptability of KT, percentage 
breast tissue water, patient-reported breast heaviness/fullness, breast discomfort and breast 
redness.   
Results:  Recruitment for this study was an average of 2.8 participants per month.  There were 
no dropouts from either group. No adverse events or major skin side effects were recorded 
in either group.  Minor skin redness was the most common dermal change (n=5).  Compliance 
with KT was excellent.  Percentage tissue water in the worst affected breast quadrant 
reduced, on average, by 15.14% and 10.43% in both the KT group and the usual care group 
respectively. 
Conclusion:  This feasibility RCT into the use of KT in BLE has shown that recruitment to a 
larger scale RCT is feasible.  It has been demonstrated that KT is a safe and acceptable 
intervention with no adverse events and minor dermal changes.  A large, multi-centred RCT 
is now necessary to accurately assess the effect of KT in BLE.   
 
Keywords: Breast lymphoedema, breast oedema, kinesiology tape, Moisture MeterD 
Compact 
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 1 
INTRODUCTION 
 
Breast lymphoedema (BLE), sometimes termed breast oedema, is a lesser-known sequela of 
breast cancer treatments than upper limb lymphoedema.  Like upper limb lymphoedema, BLE 
is an often chronic condition, characterised by swelling of the affected breast, which is 
perhaps not surprising as the breast and ipsilateral arm share the same lymphatic drainage 
routes [1]. BLE can be attributed, in part, to the growing number of breast-conserving (non-
mastectomy) surgeries such as wide local excisions (WLE) and sentinel node biopsies (SLNB) 
performed each year [2].  The incidence of BLE has been reported in the literature as ranging 
from 0 to 90.4% across twenty-eight studies in a systematic review [3]. 
 
Lymphoedema of the breast causes problematic symptoms such as breast heaviness, redness 
and discomfort, with the latter symptom being reported in up to 69% of cases [4]. Indeed, in 
a survey by Gho and colleagues, bra discomfort was reported by 92.3% of participants who 
had lymphoedema [5].  Unlike upper limb lymphoedema, those with chronic BLE may 
experience severe pain and discomfort [6].  Pain due to severe tension of the 
lymphoedematous breast has also been documented in a case study [7].  BLE may also cause 
an unsatisfactory cosmetic appearance which can influence quality of life (QoL) [3].   Indeed, 
due to increasing numbers of breast cancer survivors, unwanted side effects of treatment 
such as BLE are beginning to demand the attention of clinicians.  However, there is a dearth 
of evidence specifically describing and quantifying the impact of BLE on quality of life.   Linnit 
and Young explored the psychological impact of BLE and noted its negative impact on family 
relationships as women reported fear of holding their children too close ‘in case they knock 
it’ and reported feeling too embarrassed to get close to their partners [8]. 
 
Certain risk factors for the development of BLE have been identified in the 
literature.  Recently, axillary surgery is noted as a primary risk factor for BLE [9,10] and 
incidences of 70% and 79% have been reported in those who have had axillary node clearance 
(ANC) surgery and radiotherapy to the affected breast [11,12]. Increased body mass index 
(BMI) and upper outer quadrant tumour site were found to correlate with BLE in a study by 
Goffman and colleagues [13].  A bra cup size of ‘C’ or more was reported to be a further risk 
factor [10, 14].  Radiotherapy dose of ≥40 Gy has also been stated to increase breast volume 
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[15].  Recipients of a photon boost, in a study by Keleman et al, were significantly more likely 
to develop breast oedema than those who received an electron boost (p<0.005) [16].   
 
In contrast to the uncomplicated circumferential measurements of upper limb lymphoedema 
using a tape measure, the clinical assessment of BLE in everyday practice is more difficult.   
Owing to the lack of availability of objective measurement tools for BLE, clinicians have had 
to rely on observation [4, 12, 13] clinical photography [17] or patient self-report [6,18].  
Objective measures such as bioimpedance [19] and ultrasound [11] have been investigated 
but are not widely available in smaller centres.  A relatively novel method of assessing local 
tissue water/swelling is the Moisture Meter-D (MMD) (Delfin Technologies Ltd, Finland) [20].   
This tool, which transmits an electromagnetic wave of 300 MHz into an open-ended coaxial 
probe, is used to non-invasively measure skin and upper subcutis tissue dielectric constant 
(TDC) [21]. TDC is directly proportional to tissue water content and so a percentage water 
reading can be read from the screen.  A study by Johansson and colleagues defined breast 
oedema as a TDC ratio exceeding 1.4:1 between the affected and healthy breast [22].  In 
practice this means that the tissue water in the affected breast skin and upper subcutis is 40% 
higher than in the contralateral breast.  A compact version of the MMD, the Moisture Meter-
D Compact (MMDC), is now being used in clinical practice [23].  It is a hand-held unit with a 
display showing percentage water rather than the TDC values directly [24].  There has been 
extensive research into TDC as an outcome measure in lymphoedema [19, 21, 25, 26] 
including reliability in upper limb lymphoedema [19, 24].  There has also been validation of 
the MMD to assess changes of tissue water in skin and subcutaneous fat [27].  There are no 
reliability or validity studies on the MMDC in BLE. 
 
A combined treatment approach for BLE typically includes skin care education, a type of 
gentle massage, manual lymphatic drainage (MLD) and the use of compression bras [28].  A 
type of medical tape called kinesiology tape (KT) has gained popularity in the treatment of 
BLE in the past number of years [8].  Kinesiology taping, commonly called K-taping, was first 
developed in Japan in the 1970s by Dr Kenzo Kase, with the treatment being introduced to 
Europe in the late 1990s [29].  It is theorised that this form of taping reduces local swelling 
and pain and improves muscle activity in lymphoedema [1], especially in the management of 
truncal oedema where treatment options are more limited [30]. 
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The evidence for the use of KT in lymphoedema is limited.  Two recent systematic reviews 
[31, 32] that included seven lymphoedema studies reported that there was ‘inconclusive 
evidence’ to support the use of KT in the management of lymphoedema.  Gatt et al.  [32], in 
a meta-analysis, compared KT to compression bandaging/garments for upper limb 
lymphoedema.  From the pooled data of five studies these authors concluded that there was 
no significant difference between KT and compression bandaging/garments in terms of limb 
volume [Weighted Mean Difference (WMD) -205.33 mL, Confidence Interval (CI) (-454.69 to 
44.04) P = 0.11].  No randomised controlled trials (RCT’s), have been identified that examine 
the use of KT in BLE.  Case reports on KT for the treatment of upper limb lymphoedema in 
three patients showed reduction in excess limb size and reduction in symptoms including 
fullness, tightness and discomfort [33]. A single centre non-randomised trial highlighted the 
safety of KT and increased functionality of the upper limb (p<0.001) post KT intervention but 
no significant reduction in limb volume [34]  Finnerty and colleagues note the relatively 
inexpensive nature of a roll of KT in the management of breast and truncal swelling when 
compared to compression garments [1]. The need for a fully-powered RCT is evident, 
however, before a large-scale study can be done a feasibility RCT should be conducted [35].  
The aim of a fully powered RCT would be to assess the effectiveness of KT in the management 
of BLE.  However, the primary objective of this feasibility RCT was to explore the feasibility of 
the recruitment of outpatients with BLE to a single centre.  Secondary objectives included: 1. 
determining the safety and acceptability of KT by questioning of participants and reporting 
any adverse events post intervention; 2. investigating the utility of the MMDC as a diagnostic 
indicator of BLE at eligibility screening and as an objective measure of breast swelling and 3. 
conducting a preliminary analysis of the data to identify potential treatment effects of KT 
within and between groups. 
 
 
 
 
 
METHODS 
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Ethical Approval 
 
Ethical approval for this study was obtained from both the Institute of Nursing and Health 
Sciences Research Governance Filter Committee, Ulster University and the Clinical Research 
Ethics Committee, Cork University Hospital.  Information leaflets were given to all participants 
and written informed consent was obtained from all participants included in the study.  All 
procedures performed in this study involving human participants were in accordance with the 
ethical standards of the aforementioned institutional research committees and with the 1964 
Helsinki declaration and its later amendments or comparable ethical standards. 
 
Study Design 
 
This study was a single-centre feasibility RCT comparing KT and usual care to usual care alone 
in the management of BLE.  One therapist treated the KT group and a different therapist 
treated the usual care alone group, to ensure continuity. Both groups received three sessions 
of MLD for twenty minutes, once per week, for three weeks, with the KT group additionally 
wearing the KT for two seven-day periods in between MLD sessions.  A blinded independent 
assessor carried out baseline measurements at Visit 1 and follow-up assessments 
immediately post treatment (Visit 4) and six weeks’ post treatment (Visit 5) (Fig.1).  
  
Insert Fig 1 here 
 
Participants 
 
Participants were recruited from consultants, breast care clinical nurse specialists (CNS’s) and 
lymphoedema therapists within the hospital. Existing patients with BLE within the 
lymphoedema service were screened and informed of the study by post, by therapists 
independent of the study.  Recruitment posters for the study were also placed at various 
locations within the hospital to allow self-referral. 
 
Eligible participants were adults aged 18-80, with unilateral breast disease, who were at least 
six weeks’ post breast surgery including SLNB/WLE and/or ANC, at least four weeks’ post 
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radiotherapy to the affected breast and who were willing to travel to the centre five times 
throughout the study.  It was decided not to have an upper limit on time since breast surgery 
to maximise recruitment.  Participants were also required to have BLE as defined by a ratio of 
≥1.1:1 % tissue water between the affected and unaffected breast, in at least one breast 
quadrant, measured by the MMDC.  Patients were excluded if they had undergone previous 
mastectomy/bilateral mastectomies, had KT to the affected breast in the three months 
preceding the study, were allergic to KT (subject to patch test), were pregnant, were on 
antibiotics for the treatment of cellulitis, were cognitively impaired, had stage IV 
cancer/widespread metastatic disease or had a breast reconstruction without nipple 
reconstruction. 
 
Setting 
 
The trial took place in the regional cancer centre of a university hospital in the south of 
Ireland. 
 
Procedure  
 
Participants who confirmed an interest in taking part in the study were screened for eligibility 
by the independent assessor at Visit 1.  The MMDC was used to confirm the presence of 
BLE.  If eligible, participants were provided with a 2cmx2cm square of KT.  Participants were 
instructed to put the patch of KT on the healthy breast 24 hours before Visit 2. 
 
Randomisation 
 
Randomisation occurred after a cooling-off period of one week.  Participants were 
randomised by an independent therapist using a computerised random number sequence, 
(generated by the independent therapist) which determined the participant allocations to 
either KT or usual care group, in groups of four [36].  The independent therapist was unaware 
of the size of the blocks.   
 
Interventions 
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The intervention group received KT and usual care.  Usual care management of BLE included 
skin care education, MLD and information on how to obtain compression bras.  KT was 
applied to cover all the affected breast in a criss-cross pattern, from just below the inferior 
clavicle to the end of the breast and as far as the lateral edge of the sternum on Visit 2, in 
1.25cm wide strips.  This was done by an experienced senior physiotherapist trained in KT for 
lymphoedema, taking care to avoid the nipple with the tape. 
 
KT was applied on Visit 2 and reapplied on Visit 3.  Participants were asked to leave the KT on 
the affected breast for these two seven-day periods, if comfortable and to remove the KT 
independently on the morning of Visit’s 3 and 4.  This protocol is based on that of Finnerty 
and colleagues in their audit on the use of KT for breast oedema [1].  On Visit 4 participants 
received MLD alone. 
 
The control group received the exact same usual care as the intervention group, without the 
application of KT.   
 
Outcome measures 
 
Primary Outcomes 
 
Feasibility of recruitment to intervention 
 
The number of participants suitable for recruitment and the number of actual volunteers was 
recorded. Any differences in retention between the control and the intervention groups were 
also noted.   
 
Safety and acceptability of KT in BLE 
 
The safety of the KT was identified by the detailed recording of any adverse events to both 
patch testing and KT intervention group.  This included dermal changes such as peeling skin, 
skin lesions/blisters, redness and broken skin in the affected breast [34].  Participants were 
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instructed to remove the tape immediately if any visual or sensory irritation occurred.  
Participants were also free to remove the tape before the seven-day intervention period was 
complete, if uncomfortable.  Adverse events were recorded weekly by the treating therapist 
to ensure the assessor remained blinded.  
 
Acceptability of the KT was investigated via standardised questioning of the participants on 
Visit’s 3 and 4 and by monitoring compliance during the intervention period.  Standardised 
questioning included three questions on the comfort of the tape, effect on skin and whether 
the participant had any concerns about the tape while in place.  Compliance was monitored 
by recording the number of days for which the tape was worn and the reason(s) for removing 
the tape. 
 
 
Secondary outcomes 
 
Percentage tissue water (Breast swelling) 
 
The MMDC measures TDC in the skin and 
subcutis non-invasively and locally in a 
few seconds.  The TDC is converted into 
water percentage on a scale from 0 to 100 
% and is displayed on the LCD screen [23].  
The breast was divided into four 
quadrants, using a skin-friendly marker, 
the edge of a laminated card and the 
nipple as the mid-point and the MMDC 
probe was placed in the middle of each quadrant.  The edge of the probe lay 1cm from the 
areola as per procedure described by Johansson et al. [22].  The same device was used for all 
tests. 
 
To determine eligibility for the trial the assessor repeated the above procedure for both the 
healthy and affected breast in the same subject.  A ratio of ≥1.1:1 between the affected and 
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healthy breast in any one quadrant was used as an indicator of BLE.  This is lower than the 
ratio of ≥1.4:1 by Johansson and colleagues [22] to include those with even mild breast 
swelling into the study.   Any positive or negative practical issues related to the use of the 
MMDC were recorded by the independent assessor. 
 
Patient-reported outcomes 
 
Breast heaviness/fullness, discomfort and redness were assessed on 10cm visual analogue 
scales (VAS) [6, 37].  
 
Statistical Analysis 
 
Descriptive statistics were used to present baseline data, e.g. percentages for nominal 
variables (e.g. affected breast) and means and standard deviation (SD) for continuous 
variables (e.g. % tissue water, VAS). The mean % tissue water in the affected breast, the worst 
affected breast quadrant for both groups and the VAS scores at baseline, post-treatment and 
at six-week follow-up are presented graphically. Statistical Package for the Social Sciences 
(SPSS) software, Version 23.0.0 was used to analyse data and graphs were formulated using 
Microsoft Excel software. 
 
 
 
 
 
 
RESULTS 
 
All the participants were female and the average age was 59 years (range from 34 to 74).  
Table 1 shows detailed demographic and clinical data for both groups.  
 
Insert Table 1 here 
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Seventeen participants were screened for eligibility, three were excluded (two did not meet 
the ≥1.1 ratio of BLE required and one did not have a nipple on the affected breast).  
Therefore, fourteen participants were randomised to either the KT or usual care group, each 
group having seven participants (Fig.2). 
 
Insert Fig 2 here 
 
Recruitment 
 
Of the seventeen people assessed for eligibility over the five-month recruitment period, 
fifteen were recruited from lymphoedema therapists within the hospital who invited existing 
patients of their service for eligibility testing.  Two were recruited from breast care CNS’s 
within the hospital.  No patients were recruited from consultants or by self-referral from study 
posters.  The average recruitment rate was 2.8 participants per month.  There were no 
differences in retention between the intervention and control groups, with no dropouts from 
either group. 
 
Safety and Acceptability of Kinesiology Tape 
 
There were no adverse events in either the KT group or usual care group.  There were no 
adverse reactions to the patch testing, therefore all the participants who were patch-tested 
took part in the intervention group.  There were no major skin side effects.  Skin redness was 
the most commonly reported dermal change amongst the intervention group (n=5).  One of 
the participants had to remove a small portion of tape from the superior part of the breast 
because of a small blister (~2mm) on day five of the second week.  This resulted in a small 
area of broken skin which closed over after one day.  
 
Five out of the seven participants in the first week and six out of the seven participants in the 
second week wore the tape continually, with no difficulty. The remaining participants noted 
some irritation and mild itchiness where the KT was loosening at the edges at day six of each 
week and removed these small sections. Overall KT compliance was 95 out of 98 potential 
days of usage (96.9%).   Five out of the seven participants reported the KT to be comfortable 
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while in place, with three stating that it felt supportive at the breast.  Those that reported the 
tape to be uncomfortable found this to be so toward the end of the seven-day period when 
the tape began to loosen. 
 
Moisture MeterD Compact  
 
The MMDC was found to be a user-friendly, useful instrument to assess and quantify breast 
swelling.  All fourteen participants in this study recorded a ratio of ≥1.4:1 between the 
affected and healthy breast in at least one breast quadrant.   
 
Percentage tissue water 
 
The worst affected/most swollen breast quadrant for thirteen out of fourteen participants 
was either of the dependent quadrants at the lower section of the breast.  The average 
percentage swelling in the worst affected breast quadrant for the KT group was 65.57% 
(±12.67) and for the usual care group was 69.43% (±8.73).  Both the KT group and the usual 
care group showed improvements in breast swelling immediately post treatment with 
average reductions of 15.14% and 10.43% respectively in the most affected quadrant.  
However, though improvements had been lost for both groups at six-week follow-up, swelling 
had not yet returned to baseline levels (Fig. 3). 
 
Insert Fig 3 here 
 
The total average breast swelling in the affected breast for the KT group at baseline was 
49.54% (±6.71) and for the usual care group was 57.79% (±8.53).  Total breast swelling in both 
groups had reduced immediately post treatment by an average of 4.61% and 4.04% 
respectively.  Again, total average breast swelling had increased at six-week follow-up but had 
not returned to baseline levels (Fig. 4).   
 
Insert Fig 4 here 
 
VAS scores 
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Patient-reported breast heaviness/fullness decreased on average for both groups from 
baseline to immediately post-treatment (1.23 in KT group and 0.53 in usual care group) and 
were higher than baseline levels at six-week follow-up.  Self-reported breast discomfort 
reduced on average by 3.47 and 1.76 for the KT and usual care groups respectively, from 
baseline to immediately post treatment.  However, these average VAS scores had not 
returned to baseline levels at six-week follow-up.  Participants in both groups did not rate 
breast redness as a problematic symptom with average scores ranging from 0.42 to 1.51.  
(Table 2) 
 
Insert Table 2 here 
 
 
 
 
DISCUSSION 
 
The primary aim of this study was to examine the feasibility of conducting an RCT to evaluate 
the effectiveness of KT and usual care versus usual care alone in the treatment of BLE, 
including issues surrounding patient recruitment, safety and acceptability of KT and outcome 
measurement.   Considering incidences of up to 90.4% for BLE have been reported in the 
literature [3], the recruitment rate of 2.8 participants per month for this feasibility study was 
relatively low.  Potential reasons for this are that in busy clinics, diagnostic evaluation of 
lymphoedema is largely focused on the upper limb [6] and information on the assessment 
and treatment of BLE is lacking [38].  All the participants in this study reported breast 
discomfort as a problem.  Therefore, the targeted direct recruitment of participants via breast 
cancer support organisations, with greater emphasis on breast discomfort, may yield larger 
numbers for eligibility screening and thus a higher recruitment rate.   
 
This is the first feasibility RCT to explore the safety and acceptability of KT in BLE.  Previous 
RCT’s have explored effectiveness and safety issues related to KT [37, 39-42] and one non-
randomised trial examined the safety of KT [34].  However, these studies focused on upper 
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limb lymphoedema only.  While there were no dropouts from the KT group in the current 
study, previous studies have reported attrition rates of 10-21% because of dermal problems 
and allergic skin reactions to KT [32].  The risk of allergic reaction to KT was mitigated in this 
study by patch testing the breast tissue for 24 hours.   
 
Wound formation was noted as a side effect in one pilot study, however details of the 
location, type and extent of wounds from KT were not described [37].  The authors reasoned 
that removal of KT is a two-handed activity and participants removed the tape by themselves 
at home with the unaffected arm.  In the current study, a 2mm blister was the worst dermal 
change noted on day 12.  The KT was removed safely by each participant as they had two free 
hands.  Intervention time for the pilot study should also be noted: five times per week for 
four weeks [37], which is more intensive than the current study.  This may also account for 
the high level of wound formations. 
 
An audit on the use of KT for breast oedema, with ten participants, provides some useful 
comparisons with the current study as intervention times for KT were the same [1].  In the 
audit four participants reported a slightly pink colour to the breast when the tape was 
removed, while in the current study the incidence of skin changes was higher at five out of 
seven participants.  Mild itchiness was reported at the edges of the tape, where it was 
loosening, by two participants at day six, a result that was reflected by one participant in the 
audit [1].  Shortening the treatment period to five instead of seven days in a future RCT may 
offset this mild dermal change.  Compliance was excellent in the current study at 96.9%, with 
all participants able to wear most of the KT for the two seven-day application periods. 
Compliance with KT in the audit group, while stated to be recorded with questionnaires, was 
not discussed in the results [1]. 
 
A strength of this study was the use of an objective measurement tool, the MMDC, to quantify 
BLE.  The lack of good quality research into interventions for BLE may be, in part, due to the 
absence of objective measures.  This over-reliance on subjective measures has served as a 
limitation in previous studies of BLE [1, 4, 6, 13, 43] and as a barrier to the effective 
management of BLE in clinical practice.  While extensive work has been completed to validate 
MMD (the predecessor of the MMDC) further studies are needed into the reliability and 
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validity of the MMDC.  This feasibility study has demonstrated its usefulness in clinical practice 
as a quick, portable, non-invasive measure of tissue swelling of the breast, which to date, has 
been difficult to measure objectively.  The TDC ratio of ≥1.4:1 between the affected and 
healthy breast suggested by Johansson et al. [22] appears to be a good indicator of BLE in this 
study, with all participants reaching this ratio in at least one quadrant of the breast.  In this 
study, the most swollen breast quadrant in thirteen out of the fourteen participants was 
either of the lower, dependent quadrants of the breast.  This occurrence has been noted 
elsewhere [4, 44].   
 
While the primary aims of this study are to assess the safety, feasibility and acceptability of 
KT in BLE, preliminary results suggest that swelling in the worst affected quadrant and in the 
total affected breast tended to improve with both interventions and at six-week follow-up 
had not returned to baseline levels.  This is a welcome result for patients with BLE, who also 
reflected this in their breast discomfort VAS scores.  Educating patients with BLE on regular 
simple lymphatic drainage (SLD) of the breast (a type of self-MLD), may help to maintain the 
reductions in breast swelling for longer.  A future RCT would be enhanced by inclusion of 
same, with compliance logs recorded by the participant at home. 
 
In this single-centre study, the decision not to have an upper limit on time since breast surgery 
was taken to maximise recruitment.  This meant participants ranged from 3.5 months to 11 
years post-op.  Therefore, those who were longer since surgery may have had more chronic 
lymphoedema.  In a potential future multi-centre trial, an upper limit of 2 years post-op may 
see greater improvements for BLE interventions.  However, even the participant who was 11 
years post-op showed improvements in percentage tissue water and VAS scores.  This 
indicates that even chronic BLE is treatable. 
 
Limitations of this feasibility study include small sample size (n=14).  Due to time constraints, 
a five-month recruitment period was the maximum achievable.  Efforts were made to capture 
participants’ experiences of the interventions by VAS scores, however no QoL outcome 
measurements were used.  QoL measures such as the European Organisation for Research 
and Treatment of Cancer (EORTC) questionnaire or the SF-36 have been used in KT studies in 
the past [32].  Data on QoL of those with BLE is scarce and a future RCT would be enhanced 
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by inclusion of QoL measures.  The therapist carrying out the KT intervention recorded any 
adverse skin changes.  This is a potential source of bias and would have been mitigated by the 
independent assessor recording these changes.  Unfortunately, due to limited resources, this 
was not possible in this feasibility study. 
 
This feasibility RCT into the use of KT in BLE has shown that recruitment to a larger scale RCT 
is feasible, although alternative strategies may be required to maximise recruitment such as 
focusing on patient support groups and extension of the five-month recruitment period.   In 
this novel study, we have shown that KT is a safe and acceptable intervention with no adverse 
events other than minor dermal changes.  Objective measurement of BLE by use of the MMDC 
has strengthened the results of this study but its reliability and validity has yet to be 
determined.  A large, multi-centred RCT, which could include a component on MMDC 
reliability and validity, is now necessary to accurately assess the effect of KT in BLE  
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VISIT 1   VISIT 2   VISIT 3   VISIT 4         VISIT 5 
Eligibility Screening Treatment 1               Treatment 2  Treatment 3          6-week follow-up
   
   Day 0   Day 7   Day 14         Day 56 
Fig. 1 Study timelines 
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 KT + Usual Care 
(n=7) 
Usual Care (n=7) 
Age 64.14±5.89 53.86±10.37 
Affected Breast   
Left 3 (43%) 2 (29%) 
Right 4 (57%) 5 (71%) 
Surgery Type   
Same day WLE and SLNB 0 3 
Same day WLE and ANC 3 1 
WLE alone 1 0 
WLE + different day ANC 1 1 
WLE and SLNB + different day ANC 1 2 
WLE+different day SLNB+different day ANC 1 0 
Total no. of surgeries 11 10 
Average no. of days since last breast surgery 2086.14±1301.3 
(636~4154) 
1090.86±914.4 
(108~2359) 
BMI   
Overweight  4 5 
Obese 3 2 
Average no. of fractions of radiotherapy 24.57±7.64 23±7.68 
Average dose of radiotherapy (Gy) 55.43 52.14 
Average no. of days since last radiotherapy 1913.71±1281.4 992.29±838.9 
No. of participants who received boost doses 
of radiotherapy 
5 4 
Presence of seroma post-op 4 2 
Presence of wound infection post-op 1 3 
Bra cup size ≥C 7 6 
 
Table 1 Comparison of participant details in the KT group and the standard care group. 
WLE=Wide local excision; ANC=Axillary node clearance; SLNB=Sentinel node biopsy; 
BMI=Body mass index; Gy=Gray 
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Fig 2 CONSORT flow diagram for trial 
Assessed for eligibility (n=17) 
Excluded (n=3) 
• Not meeting inclusion criteria 
(n=3) 
• Declined to participate (n=0) 
    
Analysed (n=7) 
 
Lost to follow-up/discontinued intervention 
(n=0) 
Allocated to intervention (n=7) 
• Received allocated intervention (n=7) 
• Did not receive allocated intervention 
(n=0) 
Lost to follow-up/discontinued intervention 
(n=0) 
Allocated to intervention (n=7) 
• Received allocated intervention (n=7) 
• Did not receive allocated intervention 
(n=0) 
Analysed (n=7) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=14) 
Enrolment 
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Fig 3 Mean % tissue water in the worst affected breast quadrant.  Error bars displayed 
denote standard deviation (SD)  
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Fig 4 Mean % tissue water (breast swelling) in the whole affected breast.  Error bars 
displayed denote standard deviation (SD) 
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Table 2 Mean VAS scores for KT and Usual Care Group including standard deviation (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 KT Group Usual Care Group 
Baseline Day 14 6 weeks 
post 
Baseline Day 14 6 weeks 
post 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Heavy/full 3.70 2.86 2.47 2.10 3.80 2.04 3.04 2.05 2.51 2.65 3.86 2.81 
Discomfort 4.96 3.54 1.49 1.44 3.16 2.10 3.49 1.52 1.73 2.04 2.57 2.03 
Redness 1.39 1.68 0.47 0.93 0.42 1.00 1.08 1.86 1.51 2.14 1.50 1.95 
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